Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for January 2011
January 3, 2011
- Inspire Announces Results of Second Phase 3 Trial with Denufosol for Cystic Fibrosis
- Mercator Therapeutics and Pepscan Therapeutics Establish Research and Licensing Collaboration
- Trace Amounts of Germ-Killing Molecules Predict Disease Survival
- First Two Clinical Phase III Studies Confirm the Profile of Nalmefene as Efficacious and Safe in Helping Individuals to Reduce their Alcohol Consumption
- Protein Wields Phosphate Group to Inhibit Cancer Metastasis
January 4, 2011
- Alnylam Demonstrates RNAi in Man with Systemically Delivered RNAi Therapeutics
- MonoSol Rx and Midatech Ltd Complete Transbuccal Insulin Delivery Study in Primate Diabetes Model
- Argenta Announces Integrated Drug Discovery Collaboration with Dr. Reddy's Laboratories Ltd
- XOMA and Servier Sign Development and Commercialization Agreement for XOMA 052
- CardioVascular BioTherapeutics Announces Diabetic Wounds Drug Phase II Clinical Trial Data
- Protandim Found to Prevent a Process that Causes Blood Vessel Blockage in New Peer-Reviewed Study From The Ohio State University
- Kiadis Pharma Signs License Agreement with Hospira to Commercialize ATIR in Europe and Asia
- Plant Offers Scientists New Insights Into Intestinal Cancer
- New Research Reveals Unexpected Biological Pathway in Glaucoma
- Protalix BioTherapeutics Announces Presentation of PRX-105 Data at the BARDA Industry Day
January 5, 2011
- Almirall and Forest Announce Positive Results from the ATTAIN Phase III Study of Aclidinium Bromide and the Phase IIb Studies with the Fixed Dose Combination with Formoterol in Moderate to Severe COPD Patients
- Medicago Announces Publication of its Phase I Study with its Pandemic H5N1 Influenza Virus-Like Particle (VLP) Vaccine Candidate
- New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion
- Zafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity
- BG Medicine Announces New Publication on Prognostic Value of Galectin-3 in Heart Failure Patients
- arGEN-X Signs Discovery and Development Alliance With Lilly
- KINAXO Enters Agreement with AstraZeneca
- Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
- Findings Published in Journal of Pharmacology and Experimental Therapeutics Demonstrate Potential for Amira Pharmaceuticals' LPA1 Receptor Antagonist as an Anti-Fibrotic Agent
- AMRI Announces Research and Licensing Agreement with Genentech
- ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
January 6, 2011
- Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine
- Aradigm to Report Expanded Results from Successful Six-Month Phase 2b Bronchiectasis Study at Biotech Showcase 2011
- Xifaxan 550 mg Tablets Demonstrated Significant Acute and Sustained Relief of Irritable Bowel Syndrome Without Constipation According to Findings Published in the New England Journal of Medicine
- Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
- Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Pfizer
- Spirogen Ltd. Announces a Research Collaboration and License Agreement With Genentech for the Discovery and Development of Antibody Drug Conjugates
- Cell Medica Signs an Exclusive License Agreement and Strengthens Collaboration With the Center for Cell and Gene Therapy, Baylor College of Medicine
- Ligand Forms Strategic Drug Development Alliance with Chiva Pharmaceuticals
- Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
- Research by the Connecticut Gastroenterology Institute at Bristol Hospital Shows Promising New Treatments for Patients with the Irritable Bowel Syndrome
- Researchers Show How TB4 Protects Human Stem Cells
- Rib-X Announces Publication Demonstrating Superior Infection Site Potency for Delafloxacin against Gram-positive Pathogens
- Iroko Pharmaceuticals Reports Encouraging Results from Study of Naproxen Formulated Using a Proprietary, Patented, Nanotechnology Platform
- Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases
January 7, 2011
- Sucampo and Takeda Initiate Third Phase 3 Clinical Trial of Lubiprostone in Opioid-Induced Bowel Dysfunction
- Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
- Omthera Pharmaceuticals Reports Favorable Pharmacokinetics Data from ECLIPSE Trial
- Anchor Therapeutics Achieves Milestone in GPCR Collaboration
- LifeCycle Pharma Announces Positive Results of Phase 2 Clinical Trial for LCP-Tacro in De Novo Liver Transplant Patients
- Pharmasset Reports Positive Results from its HCV Clinical Programs
- ZIOPHARM Oncology and Intrexon Announce Worldwide Partnership for Synthetic Biology DNA-based Oncology Therapeutics
January 9, 2011
- Vicept Therapeutics Announces Positive Phase 2 Data of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea)
- Interim Three Month Data From Ongoing Six Month XOMA 052 Phase 2a Trial Support Safety and Biological Activity
January 10, 2011
- Geron Announces Publication Demonstrating Activity of Imetelstat Against Cancer Stem Cells From Pediatric Neural Tumors
- NPS Pharmaceuticals Announces Completion of Treatment Phase in STEPS Registration Study of GATTEX in Short Bowel Syndrome
- BioSante Pharmaceuticals Confirms Female Sexual Dysfunction as an Unmet Medical Need
- Aeolus Pharmaceuticals Announces Presentation of AEOL 10150 Data at the HHS 5th Annual Public Health Emergency Medical Countermeasures Enterprise - BARDA Industry Day
- Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer
- Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
- Inhibitex Reports Positive Interim Safety and Antiviral Data from Ongoing Phase 1b Study of HCV Nucleotide Inhibitor INX-189
January 11, 2011
- TransPharma Announces Successful Results of a Phase 1 Clinical Trial of ViaDerm-Calcitonin for the Treatment of Musculoskeletal Disorders
- ACT's Joint Venture SCRMI Reports in Prestigious Scientific Journal that Embryonic Stem Cells are a Potentially Unlimited Source of Functional Platelets for Transfusion
- Phase II Clinical Trial Results Encouraging for PA-Based Women's Health Company
- Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
- Excaliard Announces Positive Results From Three Phase 2 Clinical Trials for EXC 001, Showing Significant Improvement in Both Hypertrophic and Fine Line Scarring
- New Research from Infogroup's ORC Uncovers Numerous Factors Contributing to High Pancreatic Cancer Mortality Rate
- Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse (lisdexamfetamine dimesylate) Capsules CII in Excessive Daytime Sleepiness Model
- Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
January 12, 2011
- Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
- Comparison of Medications for Heart Failure Finds Difference in Risk of Death
- Preclinical Efficacy of Inovio Pharmaceuticals' Chikungunya DNA Vaccine Featured in PLoS Neglected Tropical Diseases
- The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimer's Disease
- Drug Reduces the Increase In Fear Caused By Previous Traumatic Experiences In Mice
- Vimpat (lacosamide) Significantly Reduced Partial-Onset Seizures Regardless of the Mechanism of Action of Concomitant Antiepileptic Drugs
- Vical - Publication Highlights Allovectin-7 Phase 2 Safety and Efficacy Results in Melanoma
- XOMA Presents XOMA 3AB Data at National Biodefense Meeting
January 13, 2011
- BioCryst Announces Peramivir Phase 3 Safety & Virology Study Results and Provides a Clinical Program Update
- International Stem Cell Applauds Research Showing Parthenogenesis as a Potential Strategy for Treating Inherited Disease
- PharmAthene Presents New Anthrax Data at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
- Patients With High Blood Pressure Respond Better to Combination Therapy Rather Than Single-Drug Therapy From the Start of Treatment (Accelerate Study)
- Statement From Dr. Andrew Wakefield: No Fraud. No Hoax. No Profit Motive.
- Popular Sleep Medicine Puts Older Adults at Risk for Falls, Cognitive Impairment
- Senesco Technologies to Present at American Association for Cancer Research's Special Conference
- Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Society's 57th Annual Meeting
- Publication of Pre-clinical research on the combination of CAVATAK and chemotherapy in breast cancer
January 14, 2011
- Kancera Makes Significant Progress in Preclinical Drug Development Against Chronic Leukemia
- New Speakers Announced for the 3rd Annual Personalized Medicine Partnerships Conference
January 18, 2011
- Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
- Mirna Therapeutics and Collaborators Publish New Data on miR-34 and its Role in Cancer Stem Cells
- ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients with Metastatic Soft-Tissue or Bone Sarcomas in the Phase 3 SUCCEED Trial
- Basil Strategies: Doctors 2.0 & You Conference to Examine Impact of Web 2.0 in Healthcare from Physician Perspective
- CED Announces Early Stage Companies Presenting at 2011 Biotech/Life Science Conference
- iBIO Announces Keynote Speakers for 2011 iBIO IndEx
- U-M Researchers Find Indirect Path to Attack Breast Cancer Stem Cells
- Two-Year ZILVER PTX Trial Results Show Drug-Coated Stents Keep Leg Arteries Open: Presented at ISET 2011
January 19, 2011
- Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium
- Targacept Announces Positive Top-Line Results from Phase 2 Trial of TC-5619 in Cognitive Dysfunction in Schizophrenia
- Plexxikon Reports Overall Survival Benefit for Melanoma Patients in PLX4032 Phase 3 Trial
- AMP's SIVAC Initiative Supports Mozambique to Set Up its National Immunization Technical Advisory Group (NITAG)
- QR Pharma to Present at the 44th Winter Conference on Brain Research
- Roundtable for Reporters: Industrial Biotech Companies Discuss USDA BioPreferred Certified Biobased Product Label
- Unfolding Pathogenesis in Parkinson's
- Data on Neogenix Oncology's Novel Therapeutic Antibody NPC-1C (Ensituximab) to be Presented at ASCO's 2011 Gastrointestinal Cancers Symposium
- Protalix BioTherapeutics Presents Data on the Company's Fabry Program and Oral Enzyme Gaucher Program With Experts in the Field of Lysosomal Disorders
- Cellectis' Meganuclease Technology Used to Efficiently Prevent Viral Infection
- Tower Cancer Research Foundation to Host Colorectal Cancer Symposium
January 20, 2011
- Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Topline Phase III Results from a Study of Levomilnacipran for the Treatment of Major Depressive Disorder
- Chelsea Therapeutics Reports Data Demonstrating Sustained Symptomatic Benefit of Northera in Neurogenic Orthostatic Hypotension Over 12-Month Treatment Period
- Money meets innovation at Biotech Showcase 2011
- Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells
- Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
- Artel Announces Workshop at LabAutomation2011
- BIA and NZBIO alliance formed
- Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
- Clinical Trial Results Demonstrate Promise for First Non-suppressive HIV Drug
- MMIS, Inc. Launches the MediSpend Aggregate Spend Solution
- How does anesthesia disturb self-perception?
January 21, 2011
- 4SC Presents Update on Phase II SHELTER trial with Oral Pan-HDAC Resminostat at the 2011 Gastrointestinal Cancer Symposium
- YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
- AVEO Pharmaceuticals' Tivozanib Clinical Data Featured at 2011 ASCO Gastrointestinal Cancers Symposium
- CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
- UC Berkeley Extension Presents Spring Events on Obama, Biotechnology, Journalism, and More
- The Alzheimer's Drug Discovery Foundation (ADDF) Organizes the 5th Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs
- Former U.S. Congressman Curt Weldon to Represent Regenicin at 2011 Future of Financial Markets Conference in Mumbai
- SCHEDULE CHANGE: Roundtable for Reporters: Industrial Biotech Companies Discuss USDA BioPreferredSM Certified Biobased Product Label
- Journal of Clinical Oncology Publishes Results from Pivotal Phase 2 PROPEL Study of FOLOTYN in Relapsed or Refractory Peripheral T-Cell Lymphoma
- FibroGen Reports Interim Results of a Phase 1 / 2 Trial of FG-3019 in Locally Advanced or Metastatic Pancreatic Cancer
- BioClinica, Inc. to Present at the 21st Annual UBS Global Healthcare Services Conference on February 7, 2011 at the Grand Hyatt Hotel in New York
- Inovio Pharmaceuticals to Present at Phacilitate Vaccine Forum Washington 2011
- Keynote Speakers James C. Greenwood, President and CEO, Biotechnology Industry Organization (BIO) and G. Steven Burrill, Founder and CEO, Burrill & Company to Provide Global Insights at Life Science Innovation Northwest 2011 Conference
- NORD Hosts Forum for FDA Commissioner and Patient Leaders
- SEC Freezes Assets in Biotech Insider Trading Case
January 24, 2011
- Protalix Announces Oral Presentations at the WORLD Lysosomal Disease Network Symposium
- Cellzome: Landmark Study Demonstrates that 'Complexes Matter' in How Epigenetic Inhibitors Interact with Their Drug Targets
- Phase 1 Results of ARQ 197 c-MET Inhibitor in Colorectal Cancer Presented at ASCO 2011 Gastrointestinal Cancers Symposium
- British Journal of Psychiatry Publishes Results from Phase 3 Study of Alexza's AZ-004 for the Treatment of Agitation in Patients with Schizophrenia
- Kowa Announces Subgroup Analyses of Peretinoin (NIK-333) Phase II/III Trial in Patients Following Curative Therapy for Hepatocellular Carcinoma (HCC) Indicate Populations Who May Gain Most Benefit from Peretinoin Therapy
- Apogenix provides update in the ongoing Phase II clinical trial of APG101 to treat Glioblastoma
- Merck KGaA: Erbitux Long-Term Survival Benefit for mCRC Patients Confirmed With FOLFOX
- Culprit Found for Increased Stroke Injury With Diabetes
January 25, 2011
- Phase III Study for Eritoran Does Not Meet Primary Endpoint
- American Heart Association Rapid Access Journal Report: Lowering Blood Pressure in Middle-Aged Women Reduces Heart Disease Risk
- PharmaEngine Reports that PEP02 Met the Primary Endpoints in Phase II Studies in Gastric Cancer and Pancreatic Cancer
- Preclinical Studies Show Encapsulated Cancer Cells Slow or Stop Growth of Freely-Growing Tumors In Animals
January 26, 2011
- Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
- Update: Iroko Pharmaceuticals Reports Encouraging Results from Study of Naproxen Formulated Using a Proprietary, Patented, Nano Technology Platform
- International Stem Cell's Scientists in Collaboration with World-Leading Stem Cell Experts Extend Understanding of Human Parthenogenetic Stem Cells in Peer-Reviewed Publications
- Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer's Disease
- Study Shows Link to Mitochondrial Dysfunction in Children With Autism
January 27, 2011
- Profil Institute's CEO Presenting on Early Phase Clinical Research in India
- Newly Published Data Demonstrates Caldolor Significantly Reduces Pain and Morphine Use in Post-Operative Patients
- RXi Pharmaceuticals Announces Positive Initial Results in microRNA Therapeutics
- Synta Pharmaceuticals Announces Ganetespib (STA-9090) Non-small Cell Lung Cancer Phase 2 Interim Results to be Presented at the Upcoming IASLC 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting
- Photocure (OSE:PHO) Announces Successful Phase II Results for Cevira
- Data Published in Science Translational Medicine Point to Role of Cellular Bioenergetics as a New Mechanistic Approach to Treat Immune Disorders
- Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
January 28, 2011
January 31, 2011
- Antisoma Reports Outcome of AS1413 Phase III Trial
- Fox Chase Cancer Center Publishes Clinical Outcomes for Patient Use
- GATTEX (teduglutide) Meets Primary Efficacy Endpoint in Phase 3 Pivotal Study in Patients with Adult Short Bowel Syndrome
- Triple Negative Cancer Research Could Benefit All Breast Cancer Patients
- New Study Shows Tapentadol Extended Release (ER) May Significantly Reduce Average Pain Intensity for Diabetic Patients Suffering from Painful Peripheral Neuropathy
